Premier Alternatives

Soufflé Therapeutics

Therapeutic Devices · Watertown, MA · Founded 2021 · Privately Held (backing)

Developer of a targeted gene therapy intended to treat autoimmune diseases and cardiac diseases. Soufflé Therapeutics is based in Watertown, MA and was founded in 2021. It was valued at $345 million at its early-stage round in Oct 2025, the last priced event on record. It has raised $241 million across 1 recorded round; the latest was a $200 million Series A in Oct 2025.

PMV mark · valuation
$344.5M
Oct 2026
Priced at
its early-stage round
Oct 2025
Total raised
$240.6M
Last round
Early Stage VC (Series A)
Oct 2025

Soufflé Therapeutics key facts

as of Oct 2026
  • Developer of a targeted gene therapy intended to treat autoimmune diseases and cardiac diseases.
  • Soufflé Therapeutics is valued at approximately $344.5M as of Oct 2026, set at its early-stage round, Oct 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $240.6M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($200.0M) in Oct 2025.
  • Notable investors include Bessemer Venture Partners, Temasek Holdings, Breyer Capital, ARCH Venture Partners, Safar Partners — 13 tracked in total.
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$344.5M

Valued at $344.5M at its early-stage round, Oct 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Soufflé Therapeutics with a free account
  • ·The complete investor list: 13 names
  • ·Watch Soufflé Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Soufflé Therapeutics funding rounds

1 rounds
Oct 2025Early Stage VC (Series A)$200.0M▮
Full funding history →

Soufflé Therapeutics valuation

Soufflé Therapeutics was valued at $345 million at its early-stage round in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Soufflé Therapeutics raised?

Soufflé Therapeutics has raised $241 million across 1 recorded round since 2025. The largest was a $200 million Series A in Oct 2025.

Soufflé Therapeutics investors

13 investors are on record for Soufflé Therapeutics, including Bessemer Venture Partners, Temasek Holdings, Breyer Capital and ARCH Venture Partners. By type, the record holds 4 venture capital firms, 1 private equity firm and 1 growth equity firm. The Series A in Oct 2025 drew 9 investors.

Comparable companies

Comparable therapeutic devices names by valuation on PrivateMarketView: Saluda Medical ($435 million), LightForce ($400 million) and Galvanize Therapeutics ($300 million).

About Soufflé Therapeutics

Developer of a targeted gene therapy intended to treat autoimmune diseases and cardiac diseases. The company develops a platform for targeted, tissue-specific genetic therapy delivery through the discovery of new cell proteins and pathways that can deliver genetic payloads, enabling healthcare professionals to target macrophages and cardiac cells for the treatment of autoimmune diseases and cardiac diseases.

Industry
Therapeutic Devices
Sector
Healthcare
HQ
Watertown, MA, United States
Founded
2021
Employees
65
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.